[Use of vazaprostan in the treatment of multifocal peripheral obliterating lesions of arteries of the lower limbs].
Vazaprostan was prescribed to 13 patients with the lower limbs obliterating atherosclerosis and the coronary arteries atherosclerotic lesion (first group) and in 17--with obliterating atherosclerosis and endarteritis of the lower limbs vessels (second group). The treatment was found to be effective one in all of the patients of the first group and in 13--of the second. The authors consider vazaprostan application to be expedient in patients with the lower limbs obliterating lesions as a supplement to operative intervention and also in coincidence of this pathology with the ischemic heart disease.
Driuk
N F
NF
Mishalov
V G
VG
Pavlichenko
L N
LN
D000368:Aged; D000527:Alprostadil; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy* / Q000601:surgery; D004691:Endarterectomy; D004692:Endarteritis / Q000188:drug therapy / Q000601:surgery; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D014665:Vasodilator Agents; D000527:Alprostadil